STOCK TITAN

Arcutis Biotherapeutics, Inc. - $ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: $ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcutis Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcutis Biotherapeutics's position in the market.

Rhea-AI Summary

Arcutis Biotherapeutics reported a strong performance in Q1 2024, with net product revenues of $21.6M for its ZORYVE® franchise, showing a 675% year-over-year growth. ZORYVE cream and foam contributed $15M and $6.5M, respectively. The company expects further GTN improvements and is preparing for a key FDA decision on July 7, 2024, regarding roflumilast cream for treating atopic dermatitis. Arcutis raised $172.5M from a public offering and secured a strategic licensing agreement in Japan. The company also reported a net loss of $35.4M, an improvement from the $80.1M loss in Q1 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.65%
Tags
-
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. announced the validation of ZORYVE foam for treating Seborrheic Dermatitis across diverse hair types. A panel of experts expressed confidence in prescribing the foam for various skin and hair types based on formulation data. The use of Crodafos CES in the formulation makes ZORYVE suitable for all affected body areas, highlighting its versatility and efficacy. The company received positive feedback from the expert panel, affirming the gentle and effective nature of the foam for patients with different hair and skin types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
none
-
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) granted restricted stock units and options to 13 new employees as an inducement for joining the company. The awards were approved by the Compensation Committee of Arcutis' Board of Directors and are part of the 2022 Inducement Plan. The grants are subject to vesting conditions over four years, with stock options having a ten-year term and an exercise price of $8.84 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
Rhea-AI Summary

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) will report first quarter 2024 financial results on May 14, 2024, after the U.S. financial markets close. The company will also provide a business update and host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation material on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences earnings
-
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) appoints David Topper as Chief Financial Officer, replacing John Smither. Topper brings extensive finance, M&A, and capital markets experience. He joins from Inmagene Biopharmaceuticals with a strong track record in leading capital market activities. Topper's appointment reflects Arcutis' focus on advancing innovation in immuno-dermatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
management
-
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. grants 58,500 restricted stock units to newly hired employees under the 2022 Inducement Plan, with a vesting period of four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.49%
Tags
none
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) will participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8-11, 2024. The company's management will engage in a Fireside Chat on April 11, 2024, at 2:15 pm EDT. Investors can access the webcast on the company's website, with a replay available for 180 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
conferences
-
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) promotes Todd Tucker to senior vice president and Chief Human Resources Officer, recognizing his contribution to building the company culture and workforce capabilities. With over 25 years of industry experience, Mr. Tucker's appointment aims to strengthen Arcutis' position in immuno-dermatology and enhance employee programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none
-
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. presented positive results from the INTEGUMENT-PED Phase 3 study of roflumilast cream 0.05% for children with atopic dermatitis at the AAD annual meeting. The cream met primary and secondary endpoints, showing significant improvement in EASI-75, vIGA-AD, and itch reduction. Roflumilast cream demonstrated consistent efficacy, safety, and tolerability in children aged 2 to 5, with potential for approval as a well-tolerated treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. highlights new research revealing the gene expression profile of seborrheic dermatitis, a unique inflammatory skin disease with its own molecular signature. The study suggests distinct skin barrier disruption in seborrheic dermatitis, providing key insights into the immune response of the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none
Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

ARQT Stock Data

1.03B
74.79M
2.5%
95.84%
16.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WESTLAKE VILLAGE

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.